دسترسی نامحدود
برای کاربرانی که ثبت نام کرده اند
دانلود کتاب Biologic Therapy for Psoriasis: Cutting Edge Treatment Principles
دانلود کتاب درمان بیولوژیک برای پسوریازیس: اصول اولیه درمان
مشخصات کتاب
Biologic Therapy for Psoriasis: Cutting Edge Treatment Principles
ویرایش: [1 ed.] نویسندگان: Nicholas Brownstone (editor), Tina Bhutani (editor), Wilson Liao (editor) سری: Updates in Clinical Dermatology ISBN (شابک) : 303092937X, 9783030929381 ناشر: Springer سال نشر: 2022 تعداد صفحات: 163 [153] زبان: English فرمت فایل : PDF (درصورت درخواست کاربر به PDF، EPUB یا AZW3 تبدیل می شود) حجم فایل: 4 Mb
قیمت کتاب (تومان) : 45,000
در صورت تبدیل فایل کتاب Biologic Therapy for Psoriasis: Cutting Edge Treatment Principles به فرمت های PDF، EPUB، AZW3، MOBI و یا DJVU می توانید به پشتیبان اطلاع دهید تا فایل مورد نظر را تبدیل نمایند.
توجه داشته باشید کتاب درمان بیولوژیک برای پسوریازیس: اصول اولیه درمان نسخه زبان اصلی می باشد و کتاب ترجمه شده به فارسی نمی باشد. وبسایت اینترنشنال لایبرری ارائه دهنده کتاب های زبان اصلی می باشد و هیچ گونه کتاب ترجمه شده یا نوشته شده به فارسی را ارائه نمی دهد.
توضیحاتی در مورد کتاب درمان بیولوژیک برای پسوریازیس: اصول اولیه درمان
درمان بیولوژیک درمانی است که می‌کوشد سیستم ایمنی بیمار را برای مبارزه با یک بیماری خاص تعدیل کند. در پسوریازیس، یک اختلال پوستی که تا حدودی ناشی از سیستم ایمنی نامنظم است که منجر به ایجاد نواحی قرمز کاملاً مشخص شده پوست با پوسته‌های سفید می‌شود، درمان بیولوژیکی این پتانسیل را دارد که با به حداقل رساندن علائم این بیماری و در عین حال به حداکثر رساندن نتایج، نتایج را به میزان قابل توجهی بهبود بخشد. مشخصات ایمنی درمان
این کتاب مروری به روز و جامع در مورد درمان بیولوژیکی برای درمان پسوریازیس ارائه می دهد. با بیش از 10 عامل بیولوژیکی تایید شده توسط FDA برای پسوریازیس (که تعداد بیشتری در خط لوله قرار دارد)، سردرگمی در میان ارائه دهندگان در مورد اینکه کدام دارو برای یک بیمار خاص بهترین است وجود دارد. فصل‌ها همه عوامل بیولوژیک پسوریازیس مورد تأیید FDA (از جمله عوامل خط لوله) را برای استفاده در بیماران اطفال، بزرگسالان و سالمندان پوشش می‌دهند. این کتاب از این نظر منحصر به فرد است که نه تنها اصول درمانی پیشرفته را بر اساس آخرین تحقیقات پوشش می دهد، بلکه یکی از جامع ترین بررسی های بیولوژیک پسوریازیس در دوران کووید-19 نیز خواهد بود.
درمان بیولوژیک برای پسوریازیس یک منبع ضروری برای متخصصین پوست و متخصص پوست است. روماتولوژیست ها، دستیاران و همکاران پوست و روماتولوژی، دستیاران پزشک پوست، پرستاران و دانشجویان پزشکی. هدف نهایی این کتاب بهبود مراقبت از بیمار با مهارت بیشتر ارائه‌دهنده درماتولوژی در این درمان‌های خاص است.
توضیحاتی درمورد کتاب به خارجی
Biologic therapy is a treatment that strives to modulate a patient's immune system to fight a given disease. In psoriasis, a skin disorder that is partly caused by a dysregulated immune system resulting in well-demarcated red areas of the skin with white scales, biologic therapy has the potential to vastly improve upon patient outcomes by minimizing the symptoms of this disease while maximizing the safety profile of the therapy.
This book offers an up-to-date and comprehensive review on biologic therapy for the treatment of psoriasis. With over 10 FDA approved biologic agents for psoriasis (with more in the pipeline), confusion exists among providers regarding which agent is best for a particular patient. Chapters cover all FDA approved psoriasis biologic agents (including pipeline agents) for use in pediatric, adult, and geriatric patients. This book is unique in that it will not only cover cutting edge treatment principles based on the latest research, it will also be one of the most comprehensive reviews of psoriasis biologics in the COVID-19 era.
Biologic Therapy for Psoriasis is a must-have resource for board certified dermatologists and rheumatologists, dermatology and rheumatology residents and fellows, dermatology physician assistants, nurse practitioners and medical students. The ultimate goal of this book is to improve patient care by making the busy practicing dermatology provider more adept with these particular therapies.
فهرست مطالب
Foreword Preface Acknowledgements Contents Contributors 1: Introduction to Biologic Therapy for Psoriasis What Is Psoriasis? Pathophysiology of Psoriasis An Introduction to Biologics and a Review of Non-Biologic Systemic Medications for Psoriasis An Overview of Biologic Therapy in Psoriasis Psoriasis Outcome Measures Conclusion References 2: Laboratory Monitoring: HIV, TB and Hepatitis Introduction Human Immunodeficiency Virus Mycobacterium Tuberculosis Baseline Tuberculosis Testing Risk of Tuberculosis Reactivation TNF-α Inhibitors IL-12/23 Inhibitor IL-23 Inhibitors IL-17 Inhibitors Surveillance Testing for LTBI Treatment of Latent Tuberculosis Conclusion Hepatitis B Role of Testing Risk of Reactivation TNF-α Inhibitors IL-12/23 Inhibitor IL-23 Inhibitors IL-17 Inhibitors Treatment Regimen Management of Positive Hepatitis B Core Antibody Hepatitis C Role of Testing Risk of Reactivation and Treatment Regimen Conclusion Conclusion References 3: TNF-Alpha Class of Biologic Agents in Psoriatic Disease Introduction Efficacy of TNF-α Antagonists in the Treatment of Psoriasis Efficacy of TNF-α Antagonists in the Treatment of Psoriatic Arthritis Safety Profiles of TNF-α Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis Conclusion References 4: IL-17 Class of Biologic Agents in Psoriatic Disease Background Information IL-17 Secukinumab (Cosentyx) Brodalumab (Siliq/Kyntheum) Ixekizumab (Taltz) Bimekizumab (Bimzelx) Drug Dosing and Side Effects References 5: IL-23 Class of Biologic Agents in Psoriatic Disease Introduction A History of Psoriatic Disease and the Discovery of the Central IL-23/17 Signaling Axis Dual Inhibition of IL-12 and IL-23: Ustekinumab Selective Blockade of IL-23: Guselkumab, Tildrakizumab, and Risankizumab Guselkumab Tildrakizumab Risankizumab Mirikizumab Safety Profiles of Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab Future Directions and Summary References 6: Combination Therapy with Biologic Agents Introduction Rationale for Combination Therapy Types of Combination Therapy Other Considerations When Prescribing Combination Therapy Combining Biologics with Phototherapy Efficacy Safety Combining Biologic Agents with Methotrexate Efficacy Safety Combining Biologic Agents with Acitretin Efficacy Safety Combining Biologic Agents with Cyclosporine Efficacy Safety Combining Biologics with Apremilast Efficacy Safety Combining Biologic Agents Efficacy Safety Conclusion References 7: Biologic Agents for the Treatment of Pediatric Psoriasis Clinical Trial Data TNF Inhibitors IL-12/23 Inhibitor IL-17 Inhibitors Real-World Usage Data Approach to Biologic Initiation Special Considerations for Pediatric Psoriasis Patients with Biologics Medical Decision-Making Mode of Delivery Access Conclusion References 8: Special Site Psoriasis Nail Psoriasis: Efficacy and Safety of Biologic Treatments TNF-α Inhibitors Adalimumab Etanercept Infliximab IL-12/23 Inhibitor Ustekinumab IL-17 Inhibitor Brodalumab Ixekizumab Secukinumab IL-23 Inhibitors Guselkumab Summary Scalp Psoriasis: Efficacy and Safety of Biologic Treatments TNF-α Inhibitors Etanercept Adalimumab IL-17 Inhibitors Brodalumab Secukinumab Ixekizumab IL-23 Inhibitors Guselkumab Risankizumab Summary Genital/Inverse Psoriasis: Efficacy and Safety of Biologic Treatments IL-17 Inhibitors Ixekizumab Other Biologics Summary Palmoplantar Psoriasis: Efficacy and Safety of Biologic Treatments TNF-α Inhibitors Adalimumab Infliximab IL-23 Inhibitors Guselkumab IL-17 Inhibitors Ixekizumab Secukinumab Discussion References 9: Comparing Biologic Agents in Treatment of Psoriasis Introduction Relative Efficacy of Psoriasis Biologics in Head-to-Head Trials Etanercept as the Reference Biologic Adalimumab as the Reference Biologic Ustekinumab as the Reference Biologic Guselkumab as the Reference Biologic Secukinumab as the Reference Biologic Relative Efficacy of Psoriasis Biologics Based on Network Meta-Analyses (NMA) NMA Efficacy at 8–24 Weeks Relative Safety of Psoriasis Biologics in Head-to-Head Trials Etanercept as the Reference Biologic Adalimumab as the Reference Biologic Ustekinumab as the Reference Biologic Guselkumab as the Reference Biologic Secukinumab as the Reference Biologic Relative Safety of Psoriasis Biologics in Network Meta-Analyses (NMA) Conclusion References 10: Long-Term Registry Data for Psoriasis Biologics Introduction The Importance of Registry Studies History of Biologic Therapy Long-Term Risks of Biologics for Psoriasis Treatment How Biologic Registries Are Conducted Benefits and Limitations of Registry Studies Benefits of Registry Studies Limitations of Registries Key Findings from Psoriasis Registry Studies Concerning Biologic Agents Long-Term Safety and Tolerability PSOLAR Psonet DERMBIO Persistence on Therapy PSOLAR BADBIR DERMBIO PsoRA BIOBADADERM Real-World Efficacy Studies for Psoriasis Biologics Measuring Efficacy of Treatment Real-World Efficacy of Psoriasis Biologics PSOLAR BioCAPTURE PsoRA DERMBIO Conclusion References 11: Psoriasis Biologic Agents in Special Populations Introduction Biologics for Pregnant and Breastfeeding Patients Biologics for Patients Who Are HIV-Positive Biologics for Patients with History of Malignancy (NMSC and Lymphoma) Biologics for Geriatric Patients Biologics for Patients Undergoing Surgery Role of Biomarkers/Precision Medicine with Psoriasis Biologics Conclusion References 12: Psoriasis Biologics and the COVID-19 Pandemic: Lessons Learned Introduction COVID-19 Infection Risk and Outcomes in Psoriasis Patients on Biologics COVID-19 Vaccination Responses in Patients Receiving Biologics Teledermatology for Biologic Monitoring Lessons Learned and Implications for Future Novel Viral Outbreaks References 13: Adherence to Biologic Therapy for Psoriasis Introduction Measures of Adherence Determinants of Adherence to Biologics in Psoriasis Treatment Patient-Centered Factors Medication-Related Factors Provider-Centered Factors Adherence Associated with Biologic Treatments Ustekinumab The TNF-α Inhibitors Etanercept Adalimumab Infliximab Secukinumab Strategies to Enhance Adherence to Biologic Treatments in Psoriasis Conclusion References Index
